GA-FINEOS-CORPORATION
The FINEOS Corporation (ASX:FCL ), the leading core platform for life, accident and health insurance globally, released a set of product updates within the cloud-native FINEOS Platform that provide expanded capabilities across Group, Voluntary, and Absence Management products. The updates fulfil needs throughout the full customer spectrum across insurers, employers, and employees to support sales and service effectiveness, new product speed to market, and an enriched customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005534/en/
To gain deeper insights into the FINEOS Platform Winter Release, join the live product management panel discussion: The FINEOS Platform: Purpose-Built for Innovation and Growth on April 14, 2022 at 11:30 am ET.
"This release marks another significant step forward in how the FINEOS Platform serves all parts of the Group, Voluntary, and Absence value chain. We are solving more problems for our customers and doing so in uniquely seamless ways,” said Eoin Kirwan, Chief Product Officer, FINEOS.
The FINEOS Platform Group, Voluntary, and Absence Management Enhancements Include:
Sales and Underwriting Effectiveness
- Integrated Experience Rating: NextGen functionality for the underwriting and actuarial teams to drive profitability across their book of business. Via an embedded user experience, an underwriter can leverage prior claims experience to provide the best appropriate rate for the customer while providing leading risk management principles for the insurer. The experience rate is blended with the manual rate based upon insurer rules and preferences.
- Enhanced Group Underwriting provides one view of the employer at time of quote: Integrated pricing flexibility and enhanced underwriting processes provides real time adjustment to changing market needs. Whole case underwriting enables optimized product bundles based on the employer’s total need and drives greater enrollment participation.
- LIMRA LDEx API Enhancements: Enhanced LIMRA LDEx APIs include absence management connectivity and data management.
New Product Speed to Market
- Voluntary Benefits Product Enhancements for Policy, Billing, and Claims: Enhanced claims integration and automation capabilities for accident, critical illness, and hospital indemnity enables insurers to leverage integrated eligibility and enrollment data for member elections to drive voluntary product claim acceleration and auto adjudication.
- Additional Member Management and Bill Processing: This release provides extended support for the variety of administrative models across group insurance and worksite for member management.
- Billing Enhancements: Enhanced list bill processing supports the increased consumer centric product and services required by the market with additional billing support for insured Paid Family and Medical Leave (PFML) policies.
Customer Experience
- Robust Employer Dashboard and Reporting Portal and APIs: Real-time data dashboards enable employers to view workforce leave information and review data in graphical views, filter the data by leave reason, groups, and dates. Reports can be exported in Excel or PDF formats to gain insight into individual case details.
- Intermittent Leave Process Improvement: This release reduces friction associated with intermittent leave, including surfacing the right level of information and automation, low-touch, and no-touch options, such as over-frequency tolerance rule.
- Paid Leave Integration: Enriched integration and automation between paid leave, unpaid leave, disability, and voluntary benefits that pertain to an employee’s single leave reason, reduces duplicate work and errors, and providing a single source of truth across the value chain for all elements of an employee’s leave claim.
“As the only purpose-built, cloud-native core insurance solution for the life, accident and health market, the FINEOS Platform remains ahead of the curve in meeting the technical and operational needs of insurers,” said Michael Kelly, CEO, FINEOS. “Deployable as an end-to-end core solution, or as components to enable incremental transformation efforts, the FINEOS Platform has something for the entire Employee Benefits value chain including better support for the sales/service process, the customer experience and the ability to deal with a broad range of products and services such as absence management,” added Kelly.
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest employee benefits insurers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative, progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform is the only purpose-built, end-to-end SaaS insurance solution for the life, accident and health market. The FINEOS AdminSuite delivers industry leading capabilities across core administration including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as one suite. The machine learning enabled FINEOS Engage solution enables robust people first digital engagement pathways and the FINEOS Insight solution provides predictive analytics and reporting across the business.
For more information, visit www.FINEOS.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005534/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
